Who are Dexmedetomidine-Dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oxymetazoline-fluticasone propionate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dexmedetomidine-Dexamethasone — Competitive Intelligence Brief

Dexmedetomidine-Dexamethasone (Dexmedetomidine-Dexamethasone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist / Corticosteroid combination. Area: Anesthesia / Critical Care / Perioperative Medicine.

marketed Alpha-2 adrenergic agonist / Corticosteroid combination Alpha-2 adrenergic receptor; Glucocorticoid receptor Anesthesia / Critical Care / Perioperative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine-Dexamethasone (Dexmedetomidine-Dexamethasone) — University of Chile. This combination drug pairs dexmedetomidine (an alpha-2 adrenergic agonist) with dexamethasone (a corticosteroid) to provide sedation and anti-inflammatory effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexmedetomidine-Dexamethasone TARGET	Dexmedetomidine-Dexamethasone	University of Chile	marketed	Alpha-2 adrenergic agonist / Corticosteroid combination	Alpha-2 adrenergic receptor; Glucocorticoid receptor
oxymetazoline-fluticasone propionate	oxymetazoline-fluticasone propionate	Brian J Lipworth	marketed	Nasal decongestant/corticosteroid combination	Alpha-2 adrenergic receptor; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist / Corticosteroid combination class)

University of Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine-Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab